Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2012 October;103(5) > Minerva Medica 2012 October;103(5):343-51

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

  MENOPAUSE: A CLOSER LOOK


Minerva Medica 2012 October;103(5):343-51

language: English

Individualizing hormone-therapy according to cardiovascular risk

Shoupe D.

Reproductive Endocrinology and Infertility Obstetrics and Gynecology Keck School of Medicine at University of Southern California, Los Angeles, CA, USA


PDF  


There is growing consensus that the benefit to risk profile for hormone therapy is high for healthy, low-risk women initiating therapy within 10 years of menopause or under age 60. However, special considerations are needed for women who are outside those boundaries or for those that have risk factors for cardiovascular disease.

top of page

Publication History

Cite this article as

Corresponding author e-mail

shoupe@usc.edu